Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

63.18 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Gilead Sciences

< Previous 1 2 3 4 5 6 7 Next >
Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine
From Gilead Sciences Inc.
Via Business Wire
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
From Gilead Sciences, Inc.
Via Business Wire
Gilead Policy Papers Show Pandemic's Impact on HIV Prevention and Care
SOURCE: Gilead Sciences 
Via 3BL Media
Exposures COVID-19
Promising Research in Fight Against Breast Cancer Being Amplified by an Active Biotech Sector
FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 20, 2021 – USA News Group – As the 2021 San Antonio Breast Cancer Symposium (SABCS) comes to a close, many of this year’s... 
Via FinancialNewsMedia
Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022
From Gilead Sciences, Inc.
Via Business Wire
Former Clinician Alain Chan Finds Opportunity to Expand Impact, Develop Personally and Professionally
SOURCE: Gilead Sciences 
Via 3BL Media
Developing Future Social Justice Leaders at Tougaloo College
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead's Rohini Mehtani, Ph.D. Reflects on The Importance of ASH21
SOURCE: Gilead Sciences 
Via 3BL Media
Russian Foundation Provides Career Guidance for Teens Living With HIV
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Announces New England Journal of Medicine Publication of Data Demonstrating Veklury® (Remdesivir) Significantly Reduced Risk of Hospitalization in High-Risk Patients With COVID-19
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences and Breast Cancer Awareness Month
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration
From Arcus Biosciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
The Global Breast Cancer Treatment Market Expected To Reach $34.06 Billion By End Of 2026
Palm Beach, FL – December 21, 2021 – FinancialNewsMedia.com News Commentary – Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the... 
Via FinancialNewsMedia
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
From Gilead Sciences, Inc.
Via Business Wire
Daiichi Sankyo Authorizes the First YESCARTA® (Axicabtagene Ciloleucel) CAR T-cell Therapy Treatment Site in Japan
From Gilead Sciences, Inc.
Via Business Wire
Saying 'Not Today' to Triple-Negative Breast Cancer: Lee Ann's Journey
SOURCE: Gilead Sciences 
Via 3BL Media
Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Yescarta® Demonstrates Durable Two-Year Clinical Benefit in Adults With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma Including Follicular Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Yescarta® Is First CAR T-cell Therapy to Report Five-Year Survival Data From Pivotal Study Showing Durable Long-Term Survival in Patients With Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Yescarta® CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over Standard of Care in Second-Line Relapsed or Refractory Large B-Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study
From Gilead Sciences, Inc.
Via Business Wire
HIV Advisory Council in Australia Taps Diverse Community Perspectives
SOURCE: Gilead Sciences 
Via 3BL Media
Exposures COVID-19
Drug Combinations and New Approvals Delivering Optimistic Results in Oncology Stocks
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 8, 2021 – USA News Group – Growing at a healthy CAGR of 14.1%, the Cancer Immunotherapy Market is being projected to hit... 
Via FinancialNewsMedia
Gilead Sciences Ranked No. 6 overall, and No. 2 in Health Care & Life Sciences Industry, in Newsweek's List of Most Responsible American Companies
SOURCE: Gilead Sciences 
Via 3BL Media
Gildead Sciences Is Proud to Be a Presenting Partner of National AIDS Memorial's World AIDS Day: December 1, 2021
SOURCE: Gilead Sciences 
Via 3BL Media
Gilead Sciences Added to the Dow Jones Sustainability World Index
SOURCE: Gilead Sciences 
Via 3BL Media
Topics Stocks
Exposures US Equities
Gilead’s Bold Ambition of Transforming Triple-Negative Breast Cancer Treatment to Be Highlighted With New Data at SABCS
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.